二甲双胍对晚期头颈癌同步放化疗患者的影响
该回顾性研究分析了2007至2010年间252例接受同步放化疗的III、IVA、IVB期头颈癌患者,其中39例接受二甲双胍治疗,219例未接受。两组无病生存和总生存几乎相同,但二甲双胍组对顺铂耐受性更差、体重下降更多、更需喂养管支持,且≥3级恶心/呕吐和血液学毒性更多。
要点
- 二甲双胍组与未用药组无病生存和总生存几乎相同。
- 二甲双胍组对顺铂耐受性更差,体重下降更多,更需喂养管支持。
- 二甲双胍组≥3级恶心/呕吐和血液学毒性更多。
核心结论
- 接受同步放化疗的头颈癌患者若同时使用二甲双胍,需要更仔细的多学科评估和支持治疗,以确保完成治疗并避免治疗相关毒性。
研究设计与样本
- 回顾性分析比较2007至2010年间252例接受同步放化疗的III、IVA、IVB期头颈癌患者的临床特征、治疗耐受性、毒性和生存,其中39例接受二甲双胍治疗,219例未接受。
主要发现
- 两组临床特征相似,无病生存和总生存几乎相同。
- 二甲双胍组对顺铂耐受性更差,体重下降更多,有接受较低放疗剂量的倾向,需要更多喂养管支持。
- 二甲双胍组≥3级恶心/呕吐和血液学毒性更多。
临床怎么用
- 作者认为,接受同步放化疗的头颈癌患者同时使用二甲双胍时,需要更仔细的多学科评估和支持治疗,以确保成功完成治疗并避免治疗相关毒性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to evaluate the impact of metformin on toxicities and survival in patients with head and neck cancer undergoing concurrent chemoradiotherapy (CRT). METHODS: We retrospectively analyzed and compared the clinical characteristics, treatment tolerance, toxicities, and survival of 252 patients with stages III, IVA, and IVB head and neck cancer undergoing concurrent CRT with and without metformin treatment between 2007 and 2010. RESULTS: Among all patients, 39 patients received metformin whereas 219 patients did not. Both groups had similar clinical characteristics and nearly identical disease-free survival and overall survival. However, the metformin group was less likely to tolerate cisplatin, experienced more weight loss, had a tendency to receive lower doses of radiotherapy, required more feeding tube support, and had grade ≥3 nausea/vomiting and hematological toxicities. CONCLUSION: Patients with head and neck cancer undergoing concurrent CRT along with metformin treatment require more careful multidisciplinary assessment and supportive care to ensure successful completion of treatment and avoid treatment-related toxicities.
引用
- Chang PH, Yeh KY, Wang CH, et al. Impact of metformin on patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy. Head Neck. 2017. PMID: 28449193. doi:10.1002/hed.24793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。